联影医疗今年以来股价涨19.44%，近5个交易日涨4.86%，近20日涨0.21%，近60日涨18.04%。 资料显示，上海联影医疗科技股份有限公司位于上海市嘉定区城北路2258号，成立日期2011年3月21 日，上市日期2022年8月22日，公司主营业务涉及提供高性能医学影像设备、放射治疗产品、生命科学 仪器及医疗数字化、智能化解决方案。主营业务收入构成为：销售医学影像诊断设备及放射治疗设备 81.29%，提供维修收入13.56%，其他(补充)4.68%，软件收入0.47%。 联影医疗所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：精准医疗、大盘、百元 股、基金重仓、融资融券等。 截至6月30日，联影医疗股东户数1.65万，较上期减少23.01%；人均流通股35953股，较上期增加 29.89%。2025年1月-6月，联影医疗实现营业收入60.16亿元，同比增长12.79%；归母净利润9.98亿元， 同比增长5.03%。 9月30日，联影医疗盘中上涨2.01%，截至10:11，报150.88元/股，成交3.38亿元，换手率0.27%，总市值 1243.49亿元。 资金流向方面，主力资金净流入 ...

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside of 15% to 35% from the current price [2][5]. Core Insights - The company reported a revenue of 10.3 billion RMB for 2024, a decrease of 9.7% year-on-year, with a net profit of 1.26 billion RMB, down 36.1% year-on-year. However, the first quarter of 2025 showed signs of recovery with a revenue of 2.48 billion RMB, up 5.4% year-on-year, and a net profit of 370 million RMB, up 1.9% year-on-year [5]. - The company plans to distribute a dividend of 0.8 RMB per 10 shares and may consider an additional mid-year dividend if conditions are met [5]. - International sales have shown strong growth, with overseas revenue reaching 2.27 billion RMB in 2024, up 35% year-on-year, accounting for 22% of total revenue. The domestic market is expected to recover in 2025 [5]. - Maintenance service revenue increased by 26.8% year-on-year to 1.36 billion RMB in 2024, while equipment sales were impacted by domestic policy changes [5]. - Profit forecasts for 2025-2027 are 1.64 billion RMB, 2.00 billion RMB, and 2.42 billion RMB, representing year-on-year growth rates of 30.3%, 22.0%, and 20.8% respectively [5][7]. Financial Summary - The company achieved a net profit of 1.974 billion RMB in 2023, with projections of 1.644 billion RMB for 2025, and an EPS of 2.0 RMB for the same year [7][10]. - The price-to-earnings ratio (P/E) is projected to be 63 times for 2025, decreasing to 42 times by 2027 [7][10]. - The company’s total revenue is expected to grow from 11.41 billion RMB in 2023 to 12.98 billion RMB in 2025 [10].